3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
3
Skin Neoplasms
2
Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Skin Diseases
1
Rectal Neoplasms
1
Rectal Diseases
1
Neoplasm Metastasis
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colonic Diseases
1
Biliary Tract Neoplasms
1
Interventions
binimetinib
2
Aminolevulinic Acid
2
palbociclib
1
ipatasertib
1
encorafenib
1
atezolizumab
1
Vemurafenib
1
Paclitaxel
1
Gonadotropin-Releasing Hormone
1
Docetaxel
1
Dacarbazine
1
Capecitabine
1
Anastrozole
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Skin Diseases
×
encorafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA